Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
- GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies
- Immatics to receive €45 Million (~$50 Million) upfront payment with potential for additional milestone and royalty payments
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced it has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.